Phase 2 Pancreatic Cancer Trial, Recruiting NCT06659705 Sponsor: Institut Curie Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 2 Pancreatic Cancer Trial, Recruiting

NCT06659705
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with pancreatic cancer (PDAC) confirmed by a tissue or cell sample test
  • A recent CT scan and MRI (done within the last month) has shown that the cancer has not spread to other parts of the body
  • You are already enrolled in, or able to enroll in, a separate related study called the HoMING study (NCT04363983)
  • You are over 18 years old
  • You are covered by a social security or health insurance scheme (in France)
  • You are willing and able to sign a consent form agreeing to take part

Who may not be able to join:

  • Adults who are under legal protection, such as those with a court-appointed guardian or similar legal arrangement
  • Women who are currently pregnant or breastfeeding
  • Women who could become pregnant and are not using a highly effective form of contraception

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Nicolas Deleval, Institut Curie

Phone: 0033156245765

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Institut Curie
Registry
ClinicalTrials.gov
Start date
2 December 2025
Est. completion
4 August 2029

Where this trial is recruiting

🇫🇷 France

Primary endpoints

EFS: Event Free Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov